Literature DB >> 35347558

Survival analysis in cancer patients with hyponatremia: effectiveness of tolvaptan treatment.

Tomoyuki Kawada1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35347558     DOI： 10.1007/s11255-022-03190-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.266


× No keyword cloud information.
  3 in total

1.  Sample size calculations for single-arm survival studies using transformations of the Kaplan-Meier estimator.

Authors:  Kengo Nagashima; Hisashi Noma; Yasunori Sato; Masahiko Gosho
Journal:  Pharm Stat       Date:  2020-12-21       Impact factor: 1.894

2.  Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.

Authors:  Jesse H Morris; Nicole M Bohm; Branden D Nemecek; Rachel Crawford; Denise Kelley; Bhavna Bhasin; Paul J Nietert; Juan Carlos Q Velez
Journal:  Am J Kidney Dis       Date:  2018-02-23       Impact factor: 8.860

3.  Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer.

Authors:  Irem Bilgetekin; Ismail Erturk; Fatma Bugdayci Basal; Cengiz Karacin; Nuri Karadurmus; Berna Oksuzoglu; Umut Demirci
Journal:  Int Urol Nephrol       Date:  2020-08-31       Impact factor: 2.266
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.